Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 76.3× sales vs its 9.2× historical median P/S.
Fair value ≈ $7.82 · price $64.97 today
Overvalued · 731% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Feel like $VRTX will do biotech investors & $XBI on the whole a solid in coming years in terms of BD
$ALPN for $4.9B in cash was back in April 2024
Since then it's been crickets, mainly license deals such as recent preclinical trispecific T cell engager from WuXi Biologics...release
Cantor Fitzgerald reiterated $TVTX at an Overweight rating.
$NVS ( $CALT - $AHKSY ( $ALPN - $VRTX))
Cantor Fitzgerald said in its note, "We'd own $TVTX for FSGS approval and a rapid launch driven by:
1) high unmet need (higher than IgAN, per our physician survey),
2) no treatment option,
3) physician familiarity with Filspari and comfort with the safety profile in the real world,
4) no competition for Filspari for several years.
Also, Filspari pricing in FSGS (~$280K+ /yr) will likely be double the IgAN price due to the double the dose tested in FSGS. Thus, for blockbuster sales in FSGS, only 4-5K patients need to be on Filspari, or 15-30% of the 15-30K FSGS addressable patients in the U.S."
$PDSB I learned that it's very tough for microcaps to go all in or mostly all in on a single blue chip partner. There are others that were more confident with what they had so went for various partners. We went down the $PRVB path whereas Mitch Gold and $ALPN did it well (smart). There are many others that are doing awesome in that way. Still very happy with the research and end result I think is good but the management should have taken notes on strategy. Iets see what happens! It's been a fun ride on the board. Here till it ends
$PDSB this absolutely a massive disappointment and no energy from the leadership I like $PRVB or $ALPN. I'll hold bit expecting tax loss. It's a bad market day but we need a business person to assist here and salvage this messy mess.
$CKPT
I really went slumming this time. I plugged in "($4.5) Billion into my Google fish in a barrel question and up pops,
"Vertex Pharmaceuticals, a Boston-based biotechnology company, acquired Alpine Immune Sciences for approximately $4.9 billion in 2024."
News which we all, of course, remember as vividly as the famous debate moment about dog consumption. Right?
Nope..NOT at all.
I didn't even know that $104 Billion MC Vertex ($VRTX) Pharmaceuticals existed before this, and had never heard of Alpine ($ALPN) or their promising pipeline of "potential," but not yet FDA approved, drugs.
Check out the $ALPN buyout chart...
And while you do, think about the fact that some would-be buyout sale agents for Checkpoint posted they'd be "happy" to take one billion -- or golly, dream big! $1.5 Billion, ya know, $10 bucks! a $CKPT share -- for a biotech that spent over a decade to get a potentially leading revenue skin cancer drug FDA approved and on the market.
Scott Boras they are not.
$ALPN I felt 65 was low for alpn. However I feel great about 65 now. The 303 data was thin. The second set of 303 patients data, released before the acquisition, were not as strong.
$ALPN I'd like to communicate off stocktwits, if you have a suggestion. I was not enamored with the 303 Igan second group of 5's performance. First group of 5 stronger.
